{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T02:13:43Z","timestamp":1774318423000,"version":"3.50.1"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10260-5","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T04:17:05Z","timestamp":1737692225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Empagliflozin in diabetic cardiomyopathy: elucidating mechanisms, therapeutic potentials, and future directions"],"prefix":"10.1007","volume":"52","author":[{"given":"Aiswarya","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poonam","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pushkar Singh","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maninder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srivalliputturu Sarath","family":"Babu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasvinder Singh","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umashanker","family":"Navik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"5","key":"10260_CR1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.2040-1124.2010.00074.x","volume":"1","author":"Y Seino","year":"2010","unstructured":"Seino Y et al (2010) Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 1(5):212\u2013228","journal-title":"J Diabetes Investig"},{"issue":"23","key":"10260_CR2","doi-asserted-by":"crossref","first-page":"e1801401","DOI":"10.1002\/mnfr.201801401","volume":"63","author":"U Navik","year":"2019","unstructured":"Navik U et al (2019) Dietary supplementation of Methyl Donor l-Methionine alters epigenetic modification in type 2 diabetes. Mol Nutr Food Res 63(23):e1801401","journal-title":"Mol Nutr Food Res"},{"issue":"10397","key":"10260_CR3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"GBD Diabetes Collaborators","year":"2023","unstructured":"Diabetes Collaborators GBD (2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of Disease Study 2021. Lancet 402(10397):203\u2013234","journal-title":"Lancet"},{"issue":"10","key":"10260_CR4","first-page":"e11100","volume":"12","author":"MP Zaveri","year":"2020","unstructured":"Zaveri MP et al (2020) Diabetic Cardiomyopathy as a clinical entity: is it a myth? Cureus 12(10):e11100","journal-title":"Cureus"},{"key":"10260_CR5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.yjmcc.2012.06.008","volume":"55","author":"PA Crawford","year":"2013","unstructured":"Crawford PA, Schaffer JE (2013) Metabolic stress in the myocardium: adaptations of gene expression. J Mol Cell Cardiol 55:130\u2013138","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"10260_CR6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/1479164118787415","volume":"15","author":"S Bouthoorn","year":"2018","unstructured":"Bouthoorn S et al (2018) The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: a systematic review and meta-analysis. Diab Vasc Dis Res 15(6):477\u2013493","journal-title":"Diab Vasc Dis Res"},{"issue":"4","key":"10260_CR7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00592-013-0455-0","volume":"50","author":"E Konduracka","year":"2013","unstructured":"Konduracka E et al (2013) Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study. Acta Diabetol 50(4):597\u2013606","journal-title":"Acta Diabetol"},{"key":"10260_CR8","doi-asserted-by":"crossref","unstructured":"Tan Y et al (2020) Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol 17(9):585\u2013607","DOI":"10.1038\/s41569-020-0339-2"},{"issue":"9","key":"10260_CR9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41569-020-0339-2","volume":"17","author":"Y Tan","year":"2020","unstructured":"Tan Y et al (2020) Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol 17(9):585\u2013607","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10260_CR10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jjcc.2020.05.009","volume":"77","author":"H Kanamori","year":"2021","unstructured":"Kanamori H et al (2021) Morphological characteristics in diabetic cardiomyopathy associated with autophagy. J Cardiol 77(1):30\u201340","journal-title":"J Cardiol"},{"issue":"9","key":"10260_CR11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41569-020-0339-2","volume":"17","author":"Y Tan","year":"2020","unstructured":"Tan Y et al (2020) Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Reviews Cardiol 17(9):585\u2013607","journal-title":"Nat Reviews Cardiol"},{"key":"10260_CR12","doi-asserted-by":"crossref","first-page":"695792","DOI":"10.3389\/fmed.2021.695792","volume":"8","author":"T Salvatore","year":"2021","unstructured":"Salvatore T et al (2021) The Diabetic Cardiomyopathy: the contributing pathophysiological mechanisms. Front Med (Lausanne) 8:695792","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10260_CR13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrendo.2015.216","volume":"12","author":"G Jia","year":"2016","unstructured":"Jia G, DeMarco VG, Sowers JR (2016) Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Reviews Endocrinol 12(3):144","journal-title":"Nat Reviews Endocrinol"},{"issue":"10","key":"10260_CR14","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.2337\/diabetes.51.10.3020","volume":"51","author":"P Iozzo","year":"2002","unstructured":"Iozzo P et al (2002) Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes 51(10):3020\u20133024","journal-title":"Diabetes"},{"issue":"5","key":"10260_CR15","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2337\/diabetes.51.5.1543","volume":"51","author":"A Ilercil","year":"2002","unstructured":"Ilercil A et al (2002) Associations of insulin levels with left ventricular structure and function in American indians: the strong heart study. Diabetes 51(5):1543\u20131547","journal-title":"Diabetes"},{"issue":"11","key":"10260_CR16","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.2337\/db13-0095","volume":"62","author":"Y Qi","year":"2013","unstructured":"Qi Y et al (2013) Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38\u03b1 MAPK during insulin resistance. Diabetes 62(11):3887\u20133900","journal-title":"Diabetes"},{"key":"10260_CR17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.freeradbiomed.2022.03.019","volume":"184","author":"JS Bhatti","year":"2022","unstructured":"Bhatti JS et al (2022) Oxidative stress in the pathophysiology of type 2 diabetes and related complications: current therapeutics strategies and future perspectives. Free Radic Biol Med 184:114\u2013134","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10260_CR18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/eurheartj\/ehp396","volume":"31","author":"SA Cook","year":"2010","unstructured":"Cook SA et al (2010) Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur Heart J 31(1):100\u2013111","journal-title":"Eur Heart J"},{"issue":"2","key":"10260_CR19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s12264-013-1411-2","volume":"30","author":"W Qian","year":"2014","unstructured":"Qian W, Liu F (2014) Regulation of alternative splicing of tau exon 10. Neurosci Bull 30(2):367\u2013377","journal-title":"Neurosci Bull"},{"key":"10260_CR20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fphys.2016.00125","volume":"7","author":"F Westermeier","year":"2016","unstructured":"Westermeier F et al (2016) New molecular insights of insulin in diabetic cardiomyopathy. Front Physiol 7:125","journal-title":"Front Physiol"},{"issue":"2","key":"10260_CR21","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/ehf2.14224","volume":"10","author":"J Ke","year":"2023","unstructured":"Ke J et al (2023) Diabetic cardiomyopathy: a brief summary on lipid toxicity. ESC Heart Fail 10(2):776\u2013790","journal-title":"ESC Heart Fail"},{"issue":"11\u201312","key":"10260_CR22","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1089\/ars.2005.7.1568","volume":"7","author":"P Pacher","year":"2005","unstructured":"Pacher P, Szab\u00f3 C (2005) Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal 7(11\u201312):1568\u20131580","journal-title":"Antioxid Redox Signal"},{"key":"10260_CR23","doi-asserted-by":"crossref","first-page":"p8917578","DOI":"10.1155\/2016\/8917578","volume":"2016","author":"S Bernardi","year":"2016","unstructured":"Bernardi S et al (2016) Update on RAAS Modulation for the treatment of Diabetic Cardiovascular Disease. J Diabetes Res 2016:p8917578","journal-title":"J Diabetes Res"},{"issue":"6","key":"10260_CR24","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.celrep.2014.08.036","volume":"8","author":"E Fouquerel","year":"2014","unstructured":"Fouquerel E et al (2014) ARTD1\/PARP1 negatively regulates glycolysis by inhibiting hexokinase 1 independent of NAD\u2009+\u2009depletion. Cell Rep 8(6):1819\u20131831","journal-title":"Cell Rep"},{"issue":"6","key":"10260_CR25","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","volume":"54","author":"M Brownlee","year":"2005","unstructured":"Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54(6):1615\u20131625","journal-title":"Diabetes"},{"issue":"10","key":"10260_CR26","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1172\/JCI40905","volume":"120","author":"NH Son","year":"2010","unstructured":"Son NH et al (2010) PPAR\u03b3-induced cardiolipotoxicity in mice is ameliorated by PPAR\u03b1 deficiency despite increases in fatty acid oxidation. J Clin Invest 120(10):3443\u20133454","journal-title":"J Clin Invest"},{"issue":"11","key":"10260_CR27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0968-0004(01)01958-2","volume":"26","author":"DP Brazil","year":"2001","unstructured":"Brazil DP, Hemmings BA (2001) Ten years of protein kinase B signalling: a hard akt to follow. Trends Biochem Sci 26(11):657\u2013664","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"10260_CR28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00125-017-4390-4","volume":"61","author":"G Jia","year":"2018","unstructured":"Jia G, Whaley-Connell A, Sowers JR (2018) Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia 61(1):21\u201328","journal-title":"Diabetologia"},{"issue":"3","key":"10260_CR29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacbts.2018.04.003","volume":"3","author":"M Packer","year":"2018","unstructured":"Packer M (2018) Potentiation of insulin signaling contributes to Heart failure in type 2 diabetes: a hypothesis supported by both mechanistic studies and clinical trials. JACC Basic Transl Sci 3(3):415\u2013419","journal-title":"JACC Basic Transl Sci"},{"issue":"8","key":"10260_CR30","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/CIRCRESAHA.110.217117","volume":"106","author":"P Geraldes","year":"2010","unstructured":"Geraldes P, King GL (2010) Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 106(8):1319\u20131331","journal-title":"Circ Res"},{"issue":"7\u20139","key":"10260_CR31","first-page":"581","volume":"38","author":"M Perrone","year":"2023","unstructured":"Perrone M et al (2023) Calcium homeostasis in the control of Mitophagy. Antioxid Redox Signal 38(7\u20139):581\u2013598","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"10260_CR32","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR (2018) Diabetic Cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res 122(4):624\u2013638","journal-title":"Circ Res"},{"key":"10260_CR33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.physiol.70.113006.100455","volume":"70","author":"DM Bers","year":"2008","unstructured":"Bers DM (2008) Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 70:23\u201349","journal-title":"Annu Rev Physiol"},{"issue":"10","key":"10260_CR34","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCRESAHA.118.310082","volume":"122","author":"E Bertero","year":"2018","unstructured":"Bertero E, Maack C (2018) Calcium Signaling and reactive oxygen species in Mitochondria. Circ Res 122(10):1460\u20131478","journal-title":"Circ Res"},{"issue":"1","key":"10260_CR35","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.1038\/s41598-018-24817-x","volume":"8","author":"H Tanaka","year":"2018","unstructured":"Tanaka H et al (2018) Smooth muscle-like Ca2+-regulation of actin\u2013myosin interaction in adult jellyfish striated muscle. Sci Rep 8(1):7776","journal-title":"Sci Rep"},{"issue":"4","key":"10260_CR36","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1006\/jmcc.2000.1107","volume":"32","author":"Y Teshima","year":"2000","unstructured":"Teshima Y et al (2000) Diminished expression of sarcoplasmic reticulum ca(2+)-ATPase and ryanodine sensitive ca(2+)Channel mRNA in streptozotocin-induced diabetic rat heart. J Mol Cell Cardiol 32(4):655\u2013664","journal-title":"J Mol Cell Cardiol"},{"issue":"11","key":"10260_CR37","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/CIRCRESAHA.116.306923","volume":"118","author":"MS Shah","year":"2016","unstructured":"Shah MS, Brownlee M (2016) Molecular and Cellular mechanisms of Cardiovascular disorders in Diabetes. Circ Res 118(11):1808\u20131829","journal-title":"Circ Res"},{"key":"10260_CR38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.freeradbiomed.2014.05.016","volume":"73","author":"BE Sansbury","year":"2014","unstructured":"Sansbury BE, Hill BG (2014) Regulation of obesity and insulin resistance by nitric oxide. Free Radic Biol Med 73:383\u2013399","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"10260_CR39","doi-asserted-by":"crossref","first-page":"H2478","DOI":"10.1152\/ajpheart.00638.2005","volume":"289","author":"EE Jweied","year":"2005","unstructured":"Jweied EE et al (2005) Depressed cardiac myofilament function in human diabetes mellitus. Am J Physiol Heart Circ Physiol 289(6):H2478\u2013H2483","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5\u20136","key":"10260_CR40","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1440-1681.2007.04832.x","volume":"35","author":"L Ma","year":"2008","unstructured":"Ma L et al (2008) Abnormalities of sarcoplasmic reticulum Ca2+\u2009mobilization in aortic smooth muscle cells from streptozotocin-induced diabetic rats. Clin Exp Pharmacol Physiol 35(5\u20136):568\u2013573","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"4","key":"10260_CR41","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.2337\/diabetes.51.4.1166","volume":"51","author":"SU Trost","year":"2002","unstructured":"Trost SU et al (2002) Overexpression of the sarcoplasmic reticulum ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51(4):1166\u20131171","journal-title":"Diabetes"},{"issue":"1","key":"10260_CR42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1042\/BCJ20170631","volume":"475","author":"X Zhong","year":"2018","unstructured":"Zhong X et al (2018) Reduced expression of cardiac ryanodine receptor protects against stress-induced ventricular tachyarrhythmia, but increases the susceptibility to cardiac alternans. Biochem J 475(1):169\u2013183","journal-title":"Biochem J"},{"key":"10260_CR43","doi-asserted-by":"crossref","first-page":"1062777","DOI":"10.3389\/fnut.2022.1062777","volume":"9","author":"Q Wang","year":"2022","unstructured":"Wang Q et al (2022) Maillard reaction between oligopeptides and reducing sugar at body temperature: the putative anti-glycation agents. Front Nutr 9:1062777","journal-title":"Front Nutr"},{"issue":"1","key":"10260_CR44","first-page":"50","volume":"4","author":"NA Ansari","year":"2013","unstructured":"Ansari NA, Dash D (2013) Amadori glycated proteins: role in production of autoantibodies in diabetes mellitus and effect of inhibitors on non-enzymatic glycation. Aging Dis 4(1):50\u201356","journal-title":"Aging Dis"},{"key":"10260_CR45","doi-asserted-by":"crossref","first-page":"p3818196","DOI":"10.1155\/2020\/3818196","volume":"2020","author":"A Perrone","year":"2020","unstructured":"Perrone A et al (2020) Advanced Glycation End products (AGEs): Biochemistry, Signaling, Analytical methods, and Epigenetic effects. Oxid Med Cell Longev 2020:p3818196","journal-title":"Oxid Med Cell Longev"},{"issue":"12 Pt 2","key":"10260_CR46","doi-asserted-by":"crossref","first-page":"31s","DOI":"10.1016\/j.amjhyper.2004.08.021","volume":"17","author":"ME Cooper","year":"2004","unstructured":"Cooper ME (2004) Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am J Hypertens 17(12 Pt 2):31s\u201338s","journal-title":"Am J Hypertens"},{"key":"10260_CR47","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12986-018-0306-7","volume":"15","author":"JH Chen","year":"2018","unstructured":"Chen JH et al (2018) Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies. Nutr Metab (Lond) 15:72","journal-title":"Nutr Metab (Lond)"},{"issue":"1","key":"10260_CR48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10741-013-9374-y","volume":"19","author":"VL Bodiga","year":"2014","unstructured":"Bodiga VL, Eda SR, Bodiga S (2014) Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart Fail Rev 19(1):49\u201363","journal-title":"Heart Fail Rev"},{"issue":"2","key":"10260_CR49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/1440-1681.12194","volume":"41","author":"Q Yuan","year":"2014","unstructured":"Yuan Q et al (2014) Advanced glycation end-products impair na(+)\/K(+)-ATPase activity in diabetic cardiomyopathy: role of the adenosine monophosphate-activated protein kinase\/sirtuin 1 pathway. Clin Exp Pharmacol Physiol 41(2):127\u2013133","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"11","key":"10260_CR50","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1002\/2211-5463.12284","volume":"7","author":"Z Hegab","year":"2017","unstructured":"Hegab Z et al (2017) Advanced glycation end products reduce the calcium transient in cardiomyocytes by increasing production of reactive oxygen species and nitric oxide. FEBS Open Bio 7(11):1672\u20131685","journal-title":"FEBS Open Bio"},{"issue":"10","key":"10260_CR51","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1006\/jmcc.2002.2084","volume":"34","author":"R Petrova","year":"2002","unstructured":"Petrova R et al (2002) Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 34(10):1425\u20131431","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"10260_CR52","doi-asserted-by":"crossref","first-page":"H238","DOI":"10.1152\/ajpheart.2000.279.1.H238","volume":"279","author":"J Ren","year":"2000","unstructured":"Ren J, Bode AM (2000) Altered cardiac excitation-contraction coupling in ventricular myocytes from spontaneously diabetic BB rats. Am J Physiol Heart Circ Physiol 279(1):H238\u2013H244","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"7","key":"10260_CR53","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.RES.0000065620.39919.20","volume":"92","author":"R Candido","year":"2003","unstructured":"Candido R et al (2003) A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92(7):785\u2013792","journal-title":"Circ Res"},{"issue":"1","key":"10260_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbalip.2009.09.014","volume":"1801","author":"L Zhang","year":"2010","unstructured":"Zhang L et al (2010) Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle. Biochim Biophys Acta 1801(1):1\u201322","journal-title":"Biochim Biophys Acta"},{"key":"10260_CR55","doi-asserted-by":"crossref","unstructured":"Li S et al (2023) L-carnitine alleviates cardiac microvascular dysfunction in diabetic cardiomyopathy by enhancing PINK1-Parkin-dependent mitophagy through the CPT1a-PHB2-PARL pathways. Acta Physiol (Oxf) 238(3):e13975","DOI":"10.1111\/apha.13975"},{"issue":"3","key":"10260_CR56","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrendo.2015.216","volume":"12","author":"G Jia","year":"2016","unstructured":"Jia G, DeMarco VG, Sowers JR (2016) Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol 12(3):144\u2013153","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"10260_CR57","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2174\/138920110793262123","volume":"11","author":"B Turan","year":"2010","unstructured":"Turan B (2010) Role of antioxidants in redox regulation of diabetic cardiovascular complications. Curr Pharm Biotechnol 11(8):819\u2013836","journal-title":"Curr Pharm Biotechnol"},{"issue":"3","key":"10260_CR58","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.bbalip.2009.09.025","volume":"1801","author":"H Imrie","year":"2010","unstructured":"Imrie H, Abbas A, Kearney M (2010) Insulin resistance, lipotoxicity and endothelial dysfunction. Biochim Biophys Acta 1801(3):320\u2013326","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10260_CR59","doi-asserted-by":"crossref","first-page":"C1206","DOI":"10.1152\/ajpcell.00427.2021","volume":"323","author":"D Elkrief","year":"2022","unstructured":"Elkrief D et al (2022) Oxidation alters myosin-actin interaction and force generation in skeletal muscle filaments. Am J Physiol Cell Physiol 323(4):C1206\u2013c1214","journal-title":"Am J Physiol Cell Physiol"},{"key":"10260_CR60","doi-asserted-by":"crossref","unstructured":"Kim D et al (2023) Pharmacologic activation of angiotensin-converting enzyme II alleviates Diabetic Cardiomyopathy in db\/db mice by reducing reactive oxidative stress. Diabetes Metab J","DOI":"10.4093\/dmj.2022.0125"},{"issue":"5","key":"10260_CR61","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","volume":"46","author":"H Abuissa","year":"2005","unstructured":"Abuissa H et al (2005) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46(5):821\u2013826","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10260_CR62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/157016110790886947","volume":"8","author":"T Hayashi","year":"2010","unstructured":"Hayashi T, Takai S, Yamashita C (2010) Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus. Curr Vasc Pharmacol 8(2):189\u2013197","journal-title":"Curr Vasc Pharmacol"},{"issue":"1","key":"10260_CR63","doi-asserted-by":"crossref","first-page":"R144","DOI":"10.1152\/ajpregu.00191.2008","volume":"295","author":"JH Lee","year":"2008","unstructured":"Lee JH, Xia S, Ragolia L (2008) Upregulation of AT2 receptor and iNOS impairs angiotensin II-induced contraction without endothelium influence in young normotensive diabetic rats. Am J Physiology-Regulatory Integr Comp Physiol 295(1):R144\u2013R154","journal-title":"Am J Physiology-Regulatory Integr Comp Physiol"},{"issue":"12","key":"10260_CR64","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.2337\/db08-0805","volume":"57","author":"VP Singh","year":"2008","unstructured":"Singh VP et al (2008) Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes 57(12):3297\u20133306","journal-title":"Diabetes"},{"issue":"7","key":"10260_CR65","first-page":"658","volume":"19","author":"H Nasri","year":"2014","unstructured":"Nasri H, Rafieian-Kopaei M (2014) Metformin: current knowledge. J Res Med Sci 19(7):658\u2013664","journal-title":"J Res Med Sci"},{"issue":"3","key":"10260_CR66","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","volume":"142","author":"K Huynh","year":"2014","unstructured":"Huynh K et al (2014) Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther 142(3):375\u2013415","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10260_CR67","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10741-012-9313-3","volume":"18","author":"T Miki","year":"2013","unstructured":"Miki T et al (2013) Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev 18(2):149\u2013166","journal-title":"Heart Fail Rev"},{"issue":"12","key":"10260_CR68","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.amjmed.2004.10.010","volume":"117","author":"M Shah","year":"2004","unstructured":"Shah M, Kolandaivelu A, Fearon WF (2004) Pioglitazone-induced heart failure despite normal left ventricular function. Am J Med 117(12):973\u2013974","journal-title":"Am J Med"},{"key":"10260_CR69","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2018.01514","volume":"9","author":"G Borghetti","year":"2018","unstructured":"Borghetti G et al (2018) Diabetic Cardiomyopathy: current and future therapies. Beyond Glycemic Control. Front Physiol 9:1514","journal-title":"Front Physiol"},{"issue":"6","key":"10260_CR70","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","volume":"35","author":"EE Mulvihill","year":"2014","unstructured":"Mulvihill EE, Drucker DJ (2014) Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 35(6):992\u20131019","journal-title":"Endocr Rev"},{"issue":"6","key":"10260_CR71","first-page":"471","volume":"5","author":"F Paneni","year":"2015","unstructured":"Paneni F (2015) DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety. Cardiovasc Diagn Ther 5(6):471\u2013478","journal-title":"Cardiovasc Diagn Ther"},{"issue":"4","key":"10260_CR72","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2710.2002.00419.x","volume":"27","author":"M Landray","year":"2002","unstructured":"Landray M, Toescu V, Kendall M (2002) The cardioprotective role of \u03b2-blockers in patients with diabetes mellitus. J Clin Pharm Ther 27(4):233\u2013242","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"10260_CR73","doi-asserted-by":"crossref","first-page":"936","DOI":"10.2337\/diab.37.7.936","volume":"37","author":"N Afzal","year":"1988","unstructured":"Afzal N et al (1988) Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes 37(7):936\u2013942","journal-title":"Diabetes"},{"issue":"8","key":"10260_CR74","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1042\/CS20120448","volume":"124","author":"CM Thomas","year":"2013","unstructured":"Thomas CM et al (2013) Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor. Clin Sci 124(8):529\u2013545","journal-title":"Clin Sci"},{"issue":"Suppl 1","key":"10260_CR75","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/00005344-199106181-00005","volume":"18","author":"S Savage","year":"1991","unstructured":"Savage S, Miller LA, Schrier RW (1991) The future of calcium channel blocker therapy in diabetes mellitus. J Cardiovasc Pharmacol 18(Suppl 1):S19\u201324","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"10260_CR76","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4239\/wjd.v4.i5.177","volume":"4","author":"JM Pappachan","year":"2013","unstructured":"Pappachan JM et al (2013) Diabetic cardiomyopathy: pathophysiology, diagnostic evaluation and management. World J Diabetes 4(5):177","journal-title":"World J Diabetes"},{"issue":"11","key":"10260_CR77","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.lfs.2012.03.015","volume":"92","author":"P Zhao","year":"2013","unstructured":"Zhao P et al (2013) The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy. Life Sci 92(11):633\u2013638","journal-title":"Life Sci"},{"issue":"4","key":"10260_CR78","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2004-04-1559","volume":"105","author":"S Aggarwal","year":"2005","unstructured":"Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105(4):1815\u20131822","journal-title":"Blood"},{"issue":"4","key":"10260_CR79","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/01.RES.0000137877.89448.78","volume":"95","author":"C Urbich","year":"2004","unstructured":"Urbich C, Dimmeler S (2004) Endothelial progenitor cells: characterization and role in vascular biology. Circul Res 95(4):343\u2013353","journal-title":"Circul Res"},{"issue":"6","key":"10260_CR80","doi-asserted-by":"crossref","first-page":"e39836","DOI":"10.1371\/journal.pone.0039836","volume":"7","author":"F Delucchi","year":"2012","unstructured":"Delucchi F et al (2012) Resveratrol treatment reduces cardiac progenitor cell dysfunction and prevents morpho-functional ventricular remodeling in type-1 diabetic rats. PLoS ONE 7(6):e39836","journal-title":"PLoS ONE"},{"issue":"5","key":"10260_CR81","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.cell.2006.10.032","volume":"127","author":"S-W Kang","year":"2006","unstructured":"Kang S-W et al (2006) Substrate-specific translocational attenuation during ER stress defines a pre-emptive quality control pathway. Cell 127(5):999\u20131013","journal-title":"Cell"},{"issue":"5","key":"10260_CR82","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1479164114542802","volume":"11","author":"G Schernthaner","year":"2014","unstructured":"Schernthaner G, Mogensen CE, Schernthaner GH (2014) The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis Res 11(5):306\u2013323","journal-title":"Diab Vasc Dis Res"},{"issue":"1","key":"10260_CR83","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"R Grempler","year":"2012","unstructured":"Grempler R et al (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT\u20102) inhibitor: characterisation and comparison with other SGLT\u20102 inhibitors. Diabetes Obes Metabolism 14(1):83\u201390","journal-title":"Diabetes Obes Metabolism"},{"issue":"1","key":"10260_CR84","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10741-022-10228-8","volume":"28","author":"A Aimo","year":"2023","unstructured":"Aimo A et al (2023) Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin. Heart Fail Rev 28(1):179\u2013191","journal-title":"Heart Fail Rev"},{"issue":"6","key":"10260_CR85","first-page":"364","volume":"40","author":"UA Ndefo","year":"2015","unstructured":"Ndefo UA et al (2015) Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. Pharm Ther 40(6):364","journal-title":"Pharm Ther"},{"issue":"3","key":"10260_CR86","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2213-8587(22)00387-4","volume":"11","author":"LM Laffel","year":"2023","unstructured":"Laffel LM et al (2023) Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol 11(3):169\u2013181","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10260_CR87","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2174\/1573399812666160613113556","volume":"13","author":"J Levine","year":"2017","unstructured":"Levine J (2017) Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials. Curr Diabetes Rev 13(4):405\u2013423","journal-title":"Curr Diabetes Rev"},{"issue":"2","key":"10260_CR88","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","volume":"27","author":"JE Gerich","year":"2010","unstructured":"Gerich JE (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27(2):136\u2013142","journal-title":"Diabet Med"},{"issue":"6","key":"10260_CR89","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4158\/EP.14.6.782","volume":"14","author":"MA Abdul-Ghani","year":"2008","unstructured":"Abdul-Ghani MA, DeFronzo RA (2008) Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 14(6):782\u2013790","journal-title":"Endocr Pract"},{"issue":"22","key":"10260_CR90","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B et al (2015) Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128","journal-title":"N Engl J Med"},{"issue":"1","key":"10260_CR91","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41598-024-52331-w","volume":"14","author":"AA Sayour","year":"2024","unstructured":"Sayour AA et al (2024) Effect of pharmacological selectivity of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis. Sci Rep 14(1):2188","journal-title":"Sci Rep"},{"issue":"8","key":"10260_CR92","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.cardfail.2021.05.012","volume":"27","author":"G Savarese","year":"2021","unstructured":"Savarese G et al (2021) Empagliflozin in Heart failure with predicted preserved Versus reduced ejection fraction: data from the EMPA-REG OUTCOME Trial. J Card Fail 27(8):888\u2013895","journal-title":"J Card Fail"},{"issue":"11","key":"10260_CR93","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","volume":"139","author":"D Fitchett","year":"2019","unstructured":"Fitchett D et al (2019) Empagliflozin reduced mortality and hospitalization for heart failure across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation 139(11):1384\u20131395","journal-title":"Circulation"},{"issue":"8","key":"10260_CR94","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.it.2011.05.004","volume":"32","author":"D De Nardo","year":"2011","unstructured":"De Nardo D, Latz E (2011) NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol 32(8):373\u2013379","journal-title":"Trends Immunol"},{"key":"10260_CR95","doi-asserted-by":"crossref","first-page":"173040","DOI":"10.1016\/j.ejphar.2020.173040","volume":"875","author":"B Ganbaatar","year":"2020","unstructured":"Ganbaatar B et al (2020) Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. Eur J Pharmacol 875:173040","journal-title":"Eur J Pharmacol"},{"key":"10260_CR96","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcard.2022.07.048","volume":"367","author":"J Fu","year":"2022","unstructured":"Fu J et al (2022) Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role. Int J Cardiol 367:56\u201362","journal-title":"Int J Cardiol"},{"key":"10260_CR97","doi-asserted-by":"crossref","unstructured":"Uthman L et al (2022) Empagliflozin reduces oxidative stress through inhibition of the novel inflammation\/NHE\/[Na+]c\/ROS-pathway in human endothelial cells, vol 146. Biomedicine & Pharmacotherapy, p 112515","DOI":"10.1016\/j.biopha.2021.112515"},{"key":"10260_CR98","doi-asserted-by":"crossref","unstructured":"Shelke V et al (2023) Concomitant inhibition of TLR-4 and SGLT2 by phloretin and empagliflozin prevents diabetes-associated ischemic acute kidney injury. Food Funct 14(11):5391\u20135403","DOI":"10.1039\/D3FO01379K"},{"issue":"9","key":"10260_CR99","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.metabol.2012.02.013","volume":"61","author":"CH Mandavia","year":"2012","unstructured":"Mandavia CH et al (2012) Over-nutrition and metabolic cardiomyopathy. Metabolism 61(9):1205\u20131210","journal-title":"Metabolism"},{"issue":"1","key":"10260_CR100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-019-0806-4","volume":"18","author":"C Li","year":"2019","unstructured":"Li C et al (2019) SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol 18(1):1\u201313","journal-title":"Cardiovasc Diabetol"},{"issue":"15","key":"10260_CR101","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1042\/CS20190585","volume":"133","author":"M Xue","year":"2019","unstructured":"Xue M et al (2019) Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice. Clin Sci 133(15):1705\u20131720","journal-title":"Clin Sci"},{"issue":"2","key":"10260_CR102","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","volume":"117","author":"D Kolijn","year":"2021","unstructured":"Kolijn D et al (2021) Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation. Cardiovascular Res 117(2):495\u2013507","journal-title":"Cardiovascular Res"},{"issue":"15","key":"10260_CR103","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1042\/CS20190585","volume":"133","author":"M Xue","year":"2019","unstructured":"Xue M et al (2019) Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice. Clin Sci (Lond) 133(15):1705\u20131720","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"10260_CR104","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1159\/000475942","volume":"41","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Wu W (2017) The sodium-glucose co-transporter 2 inhibitor, empagliflozin, protects against diabetic cardiomyopathy by inhibition of the endoplasmic reticulum stress pathway. Cell Physiol Biochem 41(6):2503\u20132512","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"10260_CR105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C et al (2019) SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol 18(1):15","journal-title":"Cardiovasc Diabetol"},{"key":"10260_CR106","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","volume":"13","author":"S Steven","year":"2017","unstructured":"Steven S et al (2017) The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol 13:370\u2013385","journal-title":"Redox Biol"},{"key":"10260_CR107","first-page":"p9583268","volume":"2016","author":"P Xia","year":"2016","unstructured":"Xia P, Liu Y, Cheng Z (2016) Signaling pathways in Cardiac Myocyte apoptosis. Biomed Res Int 2016:p9583268","journal-title":"Biomed Res Int"},{"issue":"9","key":"10260_CR108","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/sj.embor.7400779","volume":"7","author":"E Szegezdi","year":"2006","unstructured":"Szegezdi E et al (2006) Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 7(9):880\u2013885","journal-title":"EMBO Rep"},{"issue":"3","key":"10260_CR109","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","volume":"31","author":"N Hammoudi","year":"2017","unstructured":"Hammoudi N et al (2017) Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther 31(3):233\u2013246","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10260_CR110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","volume":"16","author":"J Habibi","year":"2017","unstructured":"Habibi J et al (2017) Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol 16(1):9","journal-title":"Cardiovasc Diabetol"},{"key":"10260_CR111","doi-asserted-by":"crossref","first-page":"p7583690","DOI":"10.1155\/2019\/7583690","volume":"2019","author":"M Mocan","year":"2019","unstructured":"Mocan M et al (2019) Biomarkers of inflammation in Left Ventricular Diastolic Dysfunction. Dis Markers 2019:p7583690","journal-title":"Dis Markers"},{"issue":"5","key":"10260_CR112","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11897-021-00529-8","volume":"18","author":"S Pabel","year":"2021","unstructured":"Pabel S et al (2021) SGLT2 inhibitors and their Mode of Action in Heart failure\u2014has the mystery been Unravelled? Curr Heart Fail Rep 18(5):315\u2013328","journal-title":"Curr Heart Fail Rep"},{"issue":"2","key":"10260_CR113","first-page":"393","volume":"14","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG et al (2021) Empagliflozin ameliorates diastolic dysfunction and left ventricular Fibrosis\/Stiffness in nondiabetic heart failure: a multimodality study. JACC: Cardiovasc Imaging 14(2):393\u2013407","journal-title":"JACC: Cardiovasc Imaging"},{"key":"10260_CR114","doi-asserted-by":"crossref","unstructured":"Manolis AS, Manolis TA, Manolis AA (2023) Ketone bodies and Cardiovascular Disease: an alternate fuel source to the rescue. Int J Mol Sci, 24(4)","DOI":"10.3390\/ijms24043534"},{"key":"10260_CR115","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fphys.2017.00238","volume":"8","author":"T Liu","year":"2017","unstructured":"Liu T et al (2017) Current understanding of the pathophysiology of myocardial fibrosis and its quantitative Assessment in Heart failure. Front Physiol 8:238","journal-title":"Front Physiol"},{"issue":"1","key":"10260_CR116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","volume":"9","author":"J-C Hsu","year":"2019","unstructured":"Hsu J-C et al (2019) Effect of empagliflozin on cardiac function, adiposity, and diffuse fibrosis in patients with type 2 diabetes mellitus. Sci Rep 9(1):1\u20139","journal-title":"Sci Rep"},{"issue":"4","key":"10260_CR117","first-page":"543","volume":"36","author":"S Kang","year":"2020","unstructured":"Kang S et al (2020) Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results. Can J Cardiol 36(4):543\u2013553","journal-title":"Can J Cardiol"},{"issue":"13","key":"10260_CR118","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1161\/01.CIR.0000160352.58142.06","volume":"111","author":"T Aoyama","year":"2005","unstructured":"Aoyama T et al (2005) Serum and glucocorticoid-responsive kinase-1 regulates cardiomyocyte survival and hypertrophic response. Circulation 111(13):1652\u20131659","journal-title":"Circulation"},{"key":"10260_CR119","first-page":"53","volume":"22","author":"H Yaribeygi","year":"2023","unstructured":"Yaribeygi H et al (2023) Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art. Excli j 22:53\u201366","journal-title":"Excli j"},{"key":"10260_CR120","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.2147\/DDDT.S269514","volume":"14","author":"N Li","year":"2020","unstructured":"Li N, Zhou H (2020) SGLT2 inhibitors: a novel player in the Treatment and Prevention of Diabetic Cardiomyopathy. Drug Des Devel Ther 14:4775","journal-title":"Drug Des Devel Ther"},{"key":"10260_CR121","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fcvm.2019.00186","volume":"6","author":"Y Maejima","year":"2020","unstructured":"Maejima Y (2020) SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function. Front Cardiovasc Med 6:186","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10260_CR122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-018-0790-0","volume":"17","author":"A Durak","year":"2018","unstructured":"Durak A et al (2018) A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats. Cardiovasc Diabetol 17(1):1\u201317","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10260_CR123","doi-asserted-by":"crossref","first-page":"e12447","DOI":"10.1111\/jpi.12447","volume":"64","author":"M Ding","year":"2018","unstructured":"Ding M et al (2018) Dynamin-related protein 1\u2010mediated mitochondrial fission contributes to post\u2010traumatic cardiac dysfunction in rats and the protective effect of melatonin. J Pineal Res 64(1):e12447","journal-title":"J Pineal Res"},{"issue":"13","key":"10260_CR124","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/CIRCULATIONAHA.115.020502","volume":"133","author":"A Shirakabe","year":"2016","unstructured":"Shirakabe A et al (2016) Drp1-dependent mitochondrial autophagy plays a protective role against pressure overload\u2013induced mitochondrial dysfunction and heart failure. Circulation 133(13):1249\u20131263","journal-title":"Circulation"},{"key":"10260_CR125","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.redox.2017.02.020","volume":"12","author":"X Yang","year":"2017","unstructured":"Yang X et al (2017) Inhibition of Drp1 protects against senecionine-induced mitochondria-mediated apoptosis in primary hepatocytes and in mice. Redox Biol 12:264\u2013273","journal-title":"Redox Biol"},{"key":"10260_CR126","doi-asserted-by":"crossref","first-page":"175531","DOI":"10.1016\/j.ejphar.2023.175531","volume":"942","author":"Y Lyu","year":"2023","unstructured":"Lyu Y et al (2023) Empagliflozin ameliorates cardiac dysfunction in heart failure mice via regulating mitochondrial dynamics. Eur J Pharmacol 942:175531","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10260_CR127","doi-asserted-by":"crossref","first-page":"e13741","DOI":"10.14814\/phy2.13741","volume":"6","author":"M Mizuno","year":"2018","unstructured":"Mizuno M et al (2018) Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts. Physiological Rep 6(12):e13741","journal-title":"Physiological Rep"},{"issue":"1","key":"10260_CR128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","volume":"18","author":"Q Shao","year":"2019","unstructured":"Shao Q et al (2019) Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats. Cardiovasc Diabetol 18(1):165","journal-title":"Cardiovasc Diabetol"},{"key":"10260_CR129","doi-asserted-by":"crossref","first-page":"p1122494","DOI":"10.1155\/2022\/1122494","volume":"2022","author":"J Wang","year":"2022","unstructured":"Wang J et al (2022) Empagliflozin ameliorates Diabetic Cardiomyopathy via attenuating oxidative stress and improving mitochondrial function. Oxid Med Cell Longev 2022:p1122494","journal-title":"Oxid Med Cell Longev"},{"key":"10260_CR130","doi-asserted-by":"crossref","first-page":"1005408","DOI":"10.3389\/fcvm.2023.1005408","volume":"10","author":"T Koizumi","year":"2023","unstructured":"Koizumi T et al (2023) Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats. Front Cardiovasc Med 10:1005408","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10260_CR131","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s42003-023-04663-y","volume":"6","author":"J Choi","year":"2023","unstructured":"Choi J et al (2023) The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice. Commun Biol 6(1):278","journal-title":"Commun Biol"},{"key":"10260_CR132","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.2147\/DDDT.S269514","volume":"14","author":"N Li","year":"2020","unstructured":"Li N, Zhou H (2020) SGLT2 inhibitors: a novel player in the Treatment and Prevention of Diabetic Cardiomyopathy. Drug Des Devel Ther 14:4775\u20134788","journal-title":"Drug Des Devel Ther"},{"key":"10260_CR133","doi-asserted-by":"crossref","unstructured":"Shome JS et al (2017) Current perspectives in coronary microvascular dysfunction. Microcirculation, 24(1)","DOI":"10.1111\/micc.12340"},{"key":"10260_CR134","doi-asserted-by":"crossref","unstructured":"Zhou H et al (2017) Mff-Dependent mitochondrial fission contributes to the pathogenesis of Cardiac Microvasculature Ischemia\/Reperfusion Injury via induction of mROS-Mediated Cardiolipin Oxidation and HK2\/VDAC1 disassociation-involved mPTP opening. J Am Heart Assoc, 6(3)","DOI":"10.1161\/JAHA.116.005328"},{"issue":"2","key":"10260_CR135","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cmet.2013.12.014","volume":"19","author":"N Sawada","year":"2014","unstructured":"Sawada N et al (2014) Endothelial PGC-1\u03b1 mediates vascular dysfunction in diabetes. Cell Metab 19(2):246\u2013258","journal-title":"Cell Metab"},{"key":"10260_CR136","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","volume":"15","author":"H Zhou","year":"2018","unstructured":"Zhou H et al (2018) Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol 15:335\u2013346","journal-title":"Redox Biol"},{"issue":"4","key":"10260_CR137","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/ATVBAHA.112.300560","volume":"33","author":"PV Katakam","year":"2013","unstructured":"Katakam PV et al (2013) Depolarization of mitochondria in endothelial cells promotes cerebral artery vasodilation by activation of nitric oxide synthase. Arterioscler Thromb Vasc Biol 33(4):752\u2013759","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10260_CR138","first-page":"578","volume":"9","author":"JA Requena-Ib\u00e1\u00f1ez","year":"2021","unstructured":"Requena-Ib\u00e1\u00f1ez JA et al (2021) Mechanistic insights of Empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study. JACC: Heart Fail 9(8):578\u2013589","journal-title":"JACC: Heart Fail"},{"issue":"3","key":"10260_CR139","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4093\/dmj.2023.0190","volume":"48","author":"DH Cho","year":"2024","unstructured":"Cho DH, Park SM (2024) Epicardial adipose tissue and heart failure, friend or foe? Diabetes Metab J 48(3):373\u2013384","journal-title":"Diabetes Metab J"},{"issue":"5","key":"10260_CR140","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129(5):587\u2013597","journal-title":"Circulation"},{"issue":"1s","key":"10260_CR141","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.amjcard.2017.05.013","volume":"120","author":"B Staels","year":"2017","unstructured":"Staels B (2017) Cardiovascular Protection by Sodium Glucose Cotransporter 2 inhibitors: potential mechanisms. Am J Cardiol 120(1s):S28\u2013s36","journal-title":"Am J Cardiol"},{"issue":"12","key":"10260_CR142","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S2213-8587(15)00424-6","volume":"3","author":"MH Muskiet","year":"2015","unstructured":"Muskiet MH et al (2015) Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol 3(12):928\u2013929","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10260_CR143","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","volume":"11","author":"F Jiang","year":"2014","unstructured":"Jiang F et al (2014) Angiotensin-converting enzyme 2 and angiotensin 1\u20137: novel therapeutic targets. Nat Rev Cardiol 11(7):413\u2013426","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"10260_CR144","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrcardio.2012.145","volume":"9","author":"C Kho","year":"2012","unstructured":"Kho C, Lee A, Hajjar RJ (2012) Altered sarcoplasmic reticulum calcium cycling\u2014targets for heart failure therapy. Nat Reviews Cardiol 9(12):717","journal-title":"Nat Reviews Cardiol"},{"issue":"6868","key":"10260_CR145","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/415198a","volume":"415","author":"DM Bers","year":"2002","unstructured":"Bers DM (2002) Cardiac excitation\u2013contraction coupling. Nature 415(6868):198\u2013205","journal-title":"Nature"},{"issue":"3","key":"10260_CR146","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCRESAHA.108.175919","volume":"103","author":"T Liu","year":"2008","unstructured":"Liu T, O\u2019Rourke B (2008) Enhancing mitochondrial Ca2+\u2009uptake in myocytes from failing hearts restores energy supply and demand matching. Circul Res 103(3):279\u2013288","journal-title":"Circul Res"},{"issue":"9","key":"10260_CR147","doi-asserted-by":"crossref","first-page":"e002183","DOI":"10.1161\/JAHA.115.002183","volume":"4","author":"R Lambert","year":"2015","unstructured":"Lambert R et al (2015) Intracellular na\u2009+\u2009concentration ([Na+]i) is elevated in Diabetic hearts due to enhanced Na+-Glucose cotransport. J Am Heart Assoc 4(9):e002183","journal-title":"J Am Heart Assoc"},{"key":"10260_CR148","doi-asserted-by":"crossref","unstructured":"Moellmann J et al (2020) Empagliflozin improves left ventricular diastolic function of db\/db mice. Biochim Biophys Acta Molec Basis Dis 1866(8):165807","DOI":"10.1016\/j.bbadis.2020.165807"},{"issue":"3","key":"10260_CR149","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10741-017-9665-9","volume":"23","author":"A Kaplan","year":"2018","unstructured":"Kaplan A et al (2018) Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. Heart Fail Rev 23(3):419\u2013437","journal-title":"Heart Fail Rev"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10260-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10260-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10260-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:34:47Z","timestamp":1766853287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10260-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":149,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10260"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10260-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}